Allan Steven Jacobson
Net Worth

Last updated:

What is Allan Steven Jacobson net worth?

The estimated net worth of Dr. Allan Steven Jacobson is at least $3,687,135 as of 22 Jan 2024. He owns shares worth $606,410 as insider, has earned $1,540,725 from insider trading and has received compensation worth at least $1,540,000 in PTC Therapeutics, Inc..

What is the salary of Allan Steven Jacobson?

Dr. Allan Steven Jacobson salary is $140,000 per year as Independent Co-Founder, Chairman of Scientific Advisory Board & Director in PTC Therapeutics, Inc..

How old is Allan Steven Jacobson?

Dr. Allan Steven Jacobson is 79 years old, born in 1946.

What stocks does Allan Steven Jacobson currently own?

As insider, Dr. Allan Steven Jacobson owns shares in one company:

Company Title Shares Price per share Total value
PTC Therapeutics, Inc. (PTCT) Independent Co-Founder, Chairman of Scientific Advisory Board & Director 12,348 $49.11 $606,410

What does PTC Therapeutics, Inc. do?

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTCT logo
PTCT
PTC Therapeutics, Inc.
$49.11

Allan Steven Jacobson insider trading

PTC Therapeutics, Inc.

Dr. Allan Steven Jacobson has made 12 insider trades between 2014-2024, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of PTCT stock worth $273,800 on 22 Jan 2024.

The largest trade he's ever made was exercising 23,000 units of PTCT stock on 11 May 2023. As of 22 Jan 2024 he still owns at least 12,348 units of PTCT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 10,000 $27.38 $273,800
Option
Common Stock 10,000 $27.05 $270,500
Option
Stock Option (Right to Buy) 10,000 $27.05 $270,500
Sale
Common Stock 2,860 $56.35 $161,170
Option
Common Stock 23,000 $10.85 $249,550
Sale
Common Stock 19,040 $54.78 $1,043,068
Sale
Common Stock 1,100 $56.99 $62,687
Option
Stock Option (Right to Buy) 23,000 $10.85 $249,550
Sale
Common Stock 20,000 N/A N/A
Option
Stock Option (Right To Buy) 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Option
Common Stock 17,900 N/A N/A
Option
Stock Option (Right To Buy) 17,900 N/A N/A
Sale
Common Stock 17,900 N/A N/A
Option
Stock Option (Right To Buy) 2,100 N/A N/A
Option
Common Stock 2,100 N/A N/A
Sale
Common Stock 2,100 N/A N/A
Sale
Common Stock 5,000 N/A N/A
Sale
Common Stock 16,616 N/A N/A
Sale
Common Stock 2,000 N/A N/A
Sale
Common Stock 7,616 N/A N/A

PTC Therapeutics key executives

PTC Therapeutics, Inc. executives and other stock owners filed with the SEC: